Idroxioleic Acid

Drug Overview

Idroxioleic acid, also known as LAM561 and 2-hydroxyoleic acid (2-OHOA), is a first-in-class investigational oral Targeted Therapy developed by Spanish biotechnology company Laminar Pharmaceuticals. It belongs to an entirely novel therapeutic concept called Membrane Lipid Therapy (MLT) — a revolutionary approach that corrects the abnormal lipid composition of cancer cell membranes rather than targeting a single mutated protein.

The first-in-class brain-penetrating synthetic hydroxylated lipid idroxioleic acid activates sphingomyelin synthase expression and regulates membrane-lipid composition and mitochondrial energy production, inducing cancer cell autophagy. As of 2024–2025, idroxioleic acid has advanced into a pivotal phase 2b/3 trial for newly diagnosed glioblastoma — a disease that has seen no new standard-of-care addition since temozolomide was approved in 2005.

• Generic Name: Idroxioleic acid (LAM561; 2-OHOA; sodium 2-hydroxyoleate)
• US Brand Name: None assigned — currently investigational
• Drug Class: Sphingomyelin Synthase Activator / Membrane Lipid Therapy Agent / Targeted Therapy
• Route of Administration: Oral (liquid suspension or tablet, taken by mouth)
• FDA/EMA Approval Status: Not approved. As a designated orphan medicinal product in the EU, the CLINGLIO trial is considered pivotal in that results showing significant clinical benefit could be sufficient for a request for conditional marketing authorization in the EU, for which enabling pre-submission interactions with the EMA have been initiated. Final survival analysis is expected in Q4 2026.

What Is It and How Does It Work? (Mechanism of Action)

Idroxioleic acid works through a fundamentally different mechanism from all other anti-cancer drugs. It does not block a single protein or receptor — instead, it physically restructures the lipid architecture of the cancer cell’s outer membrane, triggering a cascade of anti-tumor consequences.

Membrane Remodeling: Cancer cells have abnormally low sphingomyelin levels in their membranes, which keeps growth-signaling proteins permanently active. Idroxioleic acid inserts into the cancer cell membrane and activates sphingomyelin synthase, restoring sphingomyelin to normal levels. This physical restructuring removes the molecular platform that keeps pro-cancer proteins such as Ras and Akt in their active positions.

Mitochondrial Disruption: 2-OHOA regulates mitochondrial membrane lipids inducing uncoupling of oxidative phosphorylation in human glioma cells but not in normal cells. By selectively disrupting energy production in cancer cells, idroxioleic acid depletes the ATP that cancer cells need to survive, while leaving normal cells unaffected — a fundamental safety advantage over conventional chemotherapy.

Autophagy and Apoptosis Induction: With survival signaling shut off and energy production compromised, cancer cells activate autophagy — a process where the cell consumes itself — ultimately leading to programmed cell death. This dual trigger of both autophagy and apoptosis makes cancer cell escape from treatment far more difficult.

Blood-Brain Barrier Penetration: 2-OHOA can penetrate the blood-brain barrier with activity in orthotopic glioma models, both as a single agent and in combination with TMZ, where it is preferentially taken up by glioma cells. This property is critically rare among anti-cancer agents and is what makes idroxioleic acid viable as a glioblastoma treatment.

FDA Approved Clinical Indications

Oncological Uses (Under Clinical Investigation — Not Approved):

• Newly Diagnosed Glioblastoma (ndGBM) — in combination with radiotherapy and temozolomide standard of care; pivotal phase 2b/3 CLINGLIO trial (NCT04250922) completed enrollment of 144 patients across 21 hospitals in Spain, Italy, France, and the UK
• Recurrent High-Grade Glioma (HGG) — studied as monotherapy in the completed phase 1/2A trial (NCT01792310)
• Advanced Solid Tumors — including breast, lung, and colorectal cancers; studied in phase 1/2A expansion cohorts

Non-Oncological Uses:

• Laminar Pharmaceuticals is also exploring idroxioleic acid in Alzheimer’s disease and metabolic conditions, though no formal oncology-unrelated clinical indications have been established.

Dosage and Administration Protocols

2-OHOA, administered as an oral suspension two or three times daily, has been generally well tolerated up to 12 g/day, while patients experienced difficulties handling the large volume of medication required at the 16 g/day dose. In the CLINGLIO pivotal trial, the dose is administered in combination with standard-of-care temozolomide and radiotherapy.

Clinical Efficacy and Research Results

The most significant development in idroxioleic acid’s clinical program comes from the landmark CLINGLIO phase 2b/3 trial (NCT04250922) — the first-ever randomized, placebo-controlled, double-blind pivotal trial of a membrane lipid therapy agent in oncology.

The pivotal phase 2b/3 trial enrolled 144 patients with newly diagnosed glioblastoma. In November 2024, after reaching 66 PFS events the independent data monitoring committee (IDMC) recommended: (1) continue the trial without modifications until 90 OS events, when the final analysis will be carried out, estimated for Q4 2026; (2) that the trial should not be stopped for reasons of safety or futility; and (3) opening the study, removing the blind.

After unblinding, Laminar released initial open-label PFS data in March 2025. Although the main primary outcome of the interim analysis — a Hazard Ratio of 0.5 for PFS — was not reached for the whole trial population, the median PFS for MGMT-methylated patients with RTOG score 3 was 56.7 weeks on the LAM561 treatment arm against 19 weeks on the placebo arm. Moreover, the median PFS for methylated patients with RTOG score 4 was 86.4 weeks on the LAM561 treatment arm against 54.7 weeks on the placebo arm.

These are clinically meaningful results in MGMT-methylated GBM patients — a subgroup known to respond to temozolomide — and represent a more than tripling of PFS in the RTOG3 cohort compared to placebo. These findings build on phase 1/2A results where of 21 HGG patients treated, 5 (24%) achieved clinical benefit including one exceptional response lasting over 2.5 years and one GBM patient achieving a 93% tumor shrinkage sustained for nearly 3 years on monotherapy.

Safety Profile and Side Effects

Black Box Warning: There is no Black Box Warning for idroxioleic acid. The IDMC has recommended the trial be continued without modifications following unblinded reviews of the available safety and efficacy data, as no safety concerns have been raised.

Common Side Effects (>10%):

• Nausea and Vomiting — the most frequently reported adverse events; reversible grade 1–2 nausea, vomiting, and diarrhoea were the most common treatment-related adverse events; managed with standard antiemetics and dose timing adjustments
• Diarrhea — predominantly grade 1–2; managed with loperamide and oral hydration
• Fatigue — mild; consistent with combined oral targeted therapy and chemoradiotherapy in the GBM setting

Serious Adverse Events:

• Gastrointestinal Dose-Limiting Toxicity: Four patients had grade 3 GI DLTs — three at 16,000 mg and one at 12,000 mg — all of which were fully reversible upon dose modification
• Volume Tolerability at High Doses: Patients experienced difficulties handling the large volume of medication required at the 16 g/day dose, experiencing frequent gastrointestinal effects that in some cases were difficult to manage — establishing 12 g/day as the optimal therapeutic dose
• Embryo-Fetal Toxicity: Theoretical risk based on membrane disruption mechanism; effective contraception required for all patients of reproductive potential

Management Strategies:

• For nausea: administer prophylactic antiemetics 30 minutes before each oral dose; divide daily dose into BID or TID schedule to reduce peak gastrointestinal exposure
• For grade 3 GI toxicity: hold immediately; resume at one dose level below after full resolution
• For diarrhea: initiate loperamide at first loose stool; maintain at least 2 liters of fluid intake daily

Connection to Stem Cell and Regenerative Medicine

Idroxioleic acid’s mitochondrial selectivity for cancer cells — and its documented sparing of normal cell populations — gives it a meaningful advantage in the context of bone marrow and stem cell preservation during combination chemoradiotherapy. Unlike temozolomide, which carries cumulative hematopoietic stem cell toxicity with repeated cycles, preclinical data show that idroxioleic acid’s OXPHOS uncoupling effect is preferentially active in cancer cells rather than normal dividing cells. This property makes it uniquely compatible with multi-cycle maintenance therapy regimens following tumor resection — an area of active investigation in the ongoing CLINGLIO long-term follow-up period extending to Q4 2026.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• MGMT promoter methylation testing — now a critical biomarker based on CLINGLIO 2025 data; methylated patients show the strongest treatment signal
• MRI brain with contrast — RANO criteria baseline assessment
• Complete blood count (CBC) and comprehensive metabolic panel
• Liver function tests (LFTs) and kidney function panel
• Pregnancy test for all women of childbearing age

Precautions During Treatment:

• Gastrointestinal tolerability must be assessed at each visit — volume of oral suspension at therapeutic doses requires careful patient education
• MRI monitoring is required at regular intervals per RANO criteria to distinguish treatment effect from pseudoprogression
• Idroxioleic acid is available only through participation in an approved clinical trial

Do’s and Don’ts:

• DO take idroxioleic acid at evenly spaced intervals to reduce gastrointestinal side effects
• DO report any persistent nausea, vomiting, or diarrhea to your care team — these are manageable but must be documented
• DO attend all scheduled MRI scans and response assessment appointments without exception
• DON’T take idroxioleic acid outside of an approved and supervised clinical trial
• DON’T adjust your daily dose volume without explicit guidance from your treating oncologist
• DON’T become pregnant during treatment — the membrane-altering mechanism carries a theoretical fetal harm risk

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Idroxioleic acid (LAM561; 2-OHOA) is an investigational drug that is not approved by the US FDA or the European Medicines Agency (EMA) for routine clinical use. Pre-submission interactions with the EMA for conditional marketing authorization are ongoing, with final overall survival analysis expected in Q4 2026. All treatment decisions must be made in consultation with a qualified oncologist or licensed healthcare professional with full knowledge of the patient’s complete medical history. This content does not replace official investigational protocol documentation or professional medical judgment.